Drug Trial Radar · NCT06790121
A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
Last checked: Nov 20, 2026Latest source record: Apr 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Jan 30, 2025
Primary completion
Feb 12, 2026
Study completion Apr 9, 2026
Sponsor
- Lead sponsor
- SanofiSanofi (SNY)
- Sponsor type
- Industry
- First posted
- Jan 23, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a parallel, Phase 2b, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy, safety, and tolerability of lunsekimig monotherapy in adult participants (aged 18 to 80 years, inclusive) with moderate-to-severe atopic dermatitis (AD). This study explores the efficacy and safety of 3 subcutaneous (SC) dose regimens of lunsekimig in adult participants with moderate-to-severe AD who have a documented history, within 6 months prior to baseline, of an inadequate response to topical treatments or for whom topical therapies are not advised. The study consists of 6 arms: 3 parallel dosing regimens and matching placebo arms. Additionally, participants have the option of engaging in a dense pharmacokinetic/pharmodynamic (PK/PD) sampling subgroup. The study duration will be up to approximately 36 weeks, including up to 4 weeks of screening, 24 weeks of treatment period and an 8-week safety follow-up period.
Conditions
- Dermatitis Atopic
Interventions
LunsekimigDrug
Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection
PlaceboDrug
Pharmaceutical form: Solution for injection in vial Route of administration: Subcutaneous injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in Eczema Area and Severity Index (EASI) score from baseline to Week 24Time frame: From Baseline throughout the study, up to Week 24
Locations
52 sites in 4 countries. Site status is shown where the registry gives one.
T. Joseph Raoof MD Inc-Site Number: 8400004
Encino, California
Integrative Skin Science and Research-Site Number: 8400002
Sacramento, California
Clinical Trials Research Institute-Site Number: 8400003
Thousand Oaks, California
Skin Care Research-Site Number: 8400013
Boca Raton, Florida
Driven Research LLC-Site Number: 8400020
Coral Gables, Florida
Revival Research Institute, LLC-Site Number: 8400021
Evans, Georgia
Treasure Valley Medical Research-Site Number: 8400026
Boise, Idaho
Southern Indiana Clinical Trials-Site Number: 8400024
New Albany, Indiana
Indiana Clinical Trials Center, P.C.-Site Number: 8400018
Plainfield, Indiana
Optima Research-Site Number: 8400019
Plainfield, Indiana
Options Research Group-Site Number: 8400012
West Lafayette, Indiana
DS Research - Kentucky-Site Number: 8400005
Louisville, Kentucky
Clinical Trials Management LLC-Site Number: 8400010
Covington, Louisiana
Beacon Clinical Research-Site Number: 8400006
Quincy, Massachusetts
Somerset Skin Centre-Site Number: 8400009
Troy, Michigan
Medisearch LLC-Site Number: 8400017
Saint Joseph, Missouri
Skin Cancer and Dermatology Institute-Site Number: 8400011
Reno, Nevada
Icahn School of Medicine at Mount Sinai-Site Number: 8400023
New York, New York
Red River Research Partners-Site Number: 8400008
Fargo, North Dakota
Health Concepts-Site Number: 8400025
Rapid City, South Dakota
DermResearch-Site Number: 8400014
Austin, Texas
Progressive Clinical Research-Site Number: 8400001
San Antonio, Texas
Burien US-WA 98168 Dermatology of Seattle and Bellevue-Site Number: 8400015
Burien, Washington
Investigational Site Number: 0203003
Prague, Czechia
Investigational Site Number: 0203001
Prague, Czechia
Investigational Site Number: 0203004
Prague, Czechia
Investigational Site Number: 0203002
Prague, Czechia
Investigational Site Number: 3920005
Asahikawa-shi, Japan
Investigational Site Number: 3920003
Fukuoka, Japan
Investigational Site Number: 3920004
Kofu, Japan
Investigational Site Number: 3920002
Mibu, Japan
Investigational Site Number: 3920006
Nerima-ku, Japan
Investigational Site Number: 3920001
Ōta-ku, Japan
Investigational Site Number: 3920008
Tachikawa-shi, Japan
Investigational Site Number: 3920007
Yokohama, Japan
Investigational Site Number: 6160014
Bochnia, Poland
Investigational Site Number: 6160006
Bydgoszcz, Poland
Investigational Site Number: 6160010
Jelenia Góra, Poland
Investigational Site Number: 6160007
Katowice, Poland
Investigational Site Number: 6160003
Katowice, Poland
Showing 40 of 52 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.